Read the first articles from our series on landmark oncology trials

Dear Prof CERASALE MORTEO, BMC Medicine is pleased to bring you the first articles from our special thematic collection on landmark oncology trials. This article collection includes carefully selected articles from invited experts on landmark trials that had the most substantial influence on the clinical practice or provided some critical evidence that enhanced our understanding in this field. It will also feature current topics in the trial design. Read the launch editorial by our esteemed Editorial Board Members (Prof. Helena Earl, Prof. Stefano Molica, and Prof. Piotr Rutkowski) and additional launch articles below. Be sure to sign up for article alertsto keep up to date with new research in this collection. Launch Articles EDITORIAL Spotlight on landmark oncology trials: the latest evidence and novel trial designs   Helena Earl, Stefano Molica and Piotr Rutkowski Abstract   |  Full text   |  PDF OPINION Immunotherapy in head and neck cancer: aiming at EXTREME precision   Petr Szturz and Jan B. Vermorken Abstract   |  Full text   |  PDF MINIREVIEW Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new   Anna Maria Frezza, Silvia Stacchiotti and Alessandro Gronchi Abstract   |  Full text   |  PDF About the Collection Cancer is a heterogeneous disease with no single treatment that is successful across all cancer types. Identification of specific genetic changes in some cancer types has been crucial in improving therapy outcomes, as it has allowed individualized targeted therapy, broadly called ‘precision medicine’. Together with the other characteristics of a tumour, like location, volume, or spread, genetic factors dictate feasible therapeutic options, which range from surgery, radiotherapy, chemotherapy, to novel targeted agents and immunotherapy. With treatment resistance being a wide-spread issue, the most promising solution seems to be the use of combination therapy with different drugs or even treatment modalities. Read more... Reasons to Publish with Us • 2016 median turnover times: initial decision three days; first decision after peer review 40 days • Portable peer review • Broad medical readership Submit your manuscript Best wishes, The BMC Medicine Team *The Impact Factor (IF) is just one measure used for evaluating the impact of research. For further information on the IF and alternative metrics used to measure the impact of research, please click here.

For further information or enquiries please contact Customer Services at:info@biomedcentral.com.

BioMed Central Ltd
236 Gray's Inn Road, London, WC1X 8HB,
United Kingdom.